JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6–12 months...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Sci
Main Authors: Harada, Daijiro, Takigawa, Nagio, Ochi, Nobuaki, Ninomiya, Takashi, Yasugi, Masayuki, Kubo, Toshio, Takeda, Hiromasa, Ichihara, Eiki, Ohashi, Kadoaki, Takata, Saburo, Tanimoto, Mitsune, Kiura, Katsuyuki
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2012
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659254/
https://ncbi.nlm.nih.gov/pubmed/22712764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02363.x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים